Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke "Heparinas"


Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- ischemic stroke
- female or male gender
- mRS (modified Rankin Scale) 0-1 (min one month before the event)
- NIHSS ≥ 6 and ≤ 25
- Age: 18-80 years
- initiation of therapy in the interval from 4.5 to 24 hours from onset of symptoms of ischemic stroke
- focal neurological deficit of at least 30 min, which was significantly obviously does not disappear before treatment
- patient will participate voluntarily and signed informed consent. Informed consent will be obtained from each patient, guardian or close relative
- patients who are unable to sign, but who are able to understand what means to participate in the study, may give informed consent through eyewitness
- willingness and ability to comply with the protocol

Exclusion Criteria

- intracranial hemorrhage confirmed by CT scan
- CT image heavy and extensive focal cerebral ischemia
- lacunar syndrome
- epileptic seizure at the beginning of ischemic stroke
- previous or planned treatment with intravenous, intra-arterial thrombolysis, mechanical recanalization or ultrasound assisted thrombolysis
- stroke, myocardial infarction, head trauma in the last 3 months
- tromboctov count below 100 000/mm ³
- therapeutically uncontrolled blood pressure: systolic blood pressure> 185 mmHg or diastolic blood pressure> 110 mmHg
- therapeutically uncontrolled blood glucose ˂ 2.77 or> 22.15 mmol / l
- Known bleeding diathesis, other coagulopathies, severe hepatopathy, severe nephropathy
- patients receiving oral anticoagulants
- current or previous life-threatening bleeding
- major surgery less than 2 weeks ago
- known malignancy
- active TB
- pregnancy
- allergy to Heparin or Fraxiparine
- known alcohol abuse and / or drugs
- active participation in another clinical study